NCT05636995View on ClinicalTrials.gov

HyperAldosteronism in Pregnancy Predicted Impacts (H.A.P.P.I. Trial)

Active, not recruitingOBSERVATIONAL
Enrollment

200

Participants

Timeline

Start Date

January 10, 2023

Primary Completion Date

March 31, 2025

Study Completion Date

December 31, 2025

Conditions
Primary HyperaldosteronismHypertensive Disorder of Pregnancy
Interventions
DIAGNOSTIC_TEST

Aldosterone/Renin Ratio

Blood sample collected to measure the aldosterone/renin ratio for the primary hyperaldosteronism screening.

Trial Locations (2)

J1H 5N4

Centre Hopitalier Universiatire de Sherbrooke, Sherbrooke

Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke

All Listed Sponsors
lead

Université de Sherbrooke

OTHER